Cargando…

Potential ovarian toxicity and infertility risk following targeted anti-cancer therapies

Unlike traditional chemotherapy agents which are generally cytotoxic to all cells, targeted anti-cancer therapies are designed to specifically target proliferation mechanisms in cancer cells but spare normal cells, resulting in high potency and reduced toxicity. There has therefore been a rapid incr...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosario, Roseanne, Cui, Wanyuan, Anderson, Richard A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346327/
https://www.ncbi.nlm.nih.gov/pubmed/35928672
http://dx.doi.org/10.1530/RAF-22-0020
_version_ 1784761625716195328
author Rosario, Roseanne
Cui, Wanyuan
Anderson, Richard A
author_facet Rosario, Roseanne
Cui, Wanyuan
Anderson, Richard A
author_sort Rosario, Roseanne
collection PubMed
description Unlike traditional chemotherapy agents which are generally cytotoxic to all cells, targeted anti-cancer therapies are designed to specifically target proliferation mechanisms in cancer cells but spare normal cells, resulting in high potency and reduced toxicity. There has therefore been a rapid increase in their development and use in clinical settings, including in curative-intent treatment regimens. However, the targets of some of these drugs including kinases, epigenetic regulatory proteins, DNA damage repair enzymes and proteasomes, have fundamental roles in governing normal ovarian physiology. Inhibiting their action could have significant consequences for ovarian function, with potentially long-lasting adverse effects which persist after cessation of treatment, but there is limited evidence of their effects on reproductive function. In this review, we will use literature that examines these pathways to infer the potential toxicity of targeted anti-cancer drugs on the ovary. LAY SUMMARY: Compared to traditional chemotherapy agents, anti-cancer therapies are thought to be highly effective at targeting cancer cells but sparing normal cells, resulting in reduced drug side effects. However, many of processes within the cells that these drugs affect are also important for the ovary to work normally, so suppressing them in this way could have long-lasting implications for female fertility. This review examines the potential toxicity of anti-cancer therapies on the ovary.
format Online
Article
Text
id pubmed-9346327
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-93463272022-08-03 Potential ovarian toxicity and infertility risk following targeted anti-cancer therapies Rosario, Roseanne Cui, Wanyuan Anderson, Richard A Reprod Fertil Review Unlike traditional chemotherapy agents which are generally cytotoxic to all cells, targeted anti-cancer therapies are designed to specifically target proliferation mechanisms in cancer cells but spare normal cells, resulting in high potency and reduced toxicity. There has therefore been a rapid increase in their development and use in clinical settings, including in curative-intent treatment regimens. However, the targets of some of these drugs including kinases, epigenetic regulatory proteins, DNA damage repair enzymes and proteasomes, have fundamental roles in governing normal ovarian physiology. Inhibiting their action could have significant consequences for ovarian function, with potentially long-lasting adverse effects which persist after cessation of treatment, but there is limited evidence of their effects on reproductive function. In this review, we will use literature that examines these pathways to infer the potential toxicity of targeted anti-cancer drugs on the ovary. LAY SUMMARY: Compared to traditional chemotherapy agents, anti-cancer therapies are thought to be highly effective at targeting cancer cells but sparing normal cells, resulting in reduced drug side effects. However, many of processes within the cells that these drugs affect are also important for the ovary to work normally, so suppressing them in this way could have long-lasting implications for female fertility. This review examines the potential toxicity of anti-cancer therapies on the ovary. Bioscientifica Ltd 2022-07-11 /pmc/articles/PMC9346327/ /pubmed/35928672 http://dx.doi.org/10.1530/RAF-22-0020 Text en © The authors https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle Review
Rosario, Roseanne
Cui, Wanyuan
Anderson, Richard A
Potential ovarian toxicity and infertility risk following targeted anti-cancer therapies
title Potential ovarian toxicity and infertility risk following targeted anti-cancer therapies
title_full Potential ovarian toxicity and infertility risk following targeted anti-cancer therapies
title_fullStr Potential ovarian toxicity and infertility risk following targeted anti-cancer therapies
title_full_unstemmed Potential ovarian toxicity and infertility risk following targeted anti-cancer therapies
title_short Potential ovarian toxicity and infertility risk following targeted anti-cancer therapies
title_sort potential ovarian toxicity and infertility risk following targeted anti-cancer therapies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346327/
https://www.ncbi.nlm.nih.gov/pubmed/35928672
http://dx.doi.org/10.1530/RAF-22-0020
work_keys_str_mv AT rosarioroseanne potentialovariantoxicityandinfertilityriskfollowingtargetedanticancertherapies
AT cuiwanyuan potentialovariantoxicityandinfertilityriskfollowingtargetedanticancertherapies
AT andersonricharda potentialovariantoxicityandinfertilityriskfollowingtargetedanticancertherapies